SELLAS Life Sciences (SLS) EPS (Diluted) Growth (5y) (2017 - 2026)
SELLAS Life Sciences (SLS) EPS (Diluted) Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.58% |
| Dec 31, 2025 | 30.30% |
| Sep 30, 2025 | 33.87% |
| Jun 30, 2025 | 32.75% |
| Mar 31, 2025 | 78.86% |
| Dec 31, 2024 | 79.24% |
| Sep 30, 2024 | 81.17% |
| Jun 30, 2024 | 75.87% |
| Mar 31, 2024 | 74.44% |
| Dec 31, 2023 | 77.65% |
| Sep 30, 2023 | 75.50% |
| Jun 30, 2023 | 75.17% |
| Mar 31, 2023 | 73.90% |
| Dec 31, 2022 | 73.48% |
| Sep 30, 2022 | 71.22% |
| Jun 30, 2022 | 71.70% |
| Mar 31, 2022 | 73.05% |
| Dec 31, 2021 | -14.87% |
| Sep 30, 2021 | 74.56% |
| Jun 30, 2021 | 76.98% |